The global gene amplification technologies market is expected to grow over the forecast period due to the growing need for genetic information for the purpose of identifying and mapping all the genes of the human genome. Key drivers for the growth of gene amplification technology industry are growing R&D in the field of molecular diagnostics, genetic testing, biological research, drug discovery, environmental monitoring, bioremediation, toxicology, animal husbandry, quality control in the food industry and forensics. The major drivers remain molecular diagnostics and Human genome project, an international research effort to sequence all the chemical base pairs that form the DNA of the species Homo sapiens. Gene amplification technique is usually done by Polymerase Chain Reaction (PCR). Polymerase Chain Reaction is the most efficient and commonly used technology for gene amplification as it enables researchers to obtain millions of copy of a gene in a very short span of time. Furthermore, substitutes and recent advancements in this technology such as Loop Mediated Isothermal Amplification (LAMP), Rolling Circle Amplification (RCA), Nucleic Acid Sequence Based Amplification (NASBA), and Self-Sustained Sequence Replication (SSR) further fuels the growth. Expiries of patents of key-players, cost-effectiveness, necessity of genetic data, and ease of use of gene amplification techniques are other important forces leading to the development of amplification technology and are expected to fuel the growth of this market.
The gene amplification technologies market is segmented on two bases which are technology, and application. On the basis of technology, isothermal DNA amplification, gene amplification technologies are classified as target amplification, cycling temperature signal gene amplification, signal amplification, cycling temperature DNA amplification, isothermal signal amplification, exponential gene amplification, and linear gene amplification. On the basis of application, the market is segmented into medical application, forensics application, paternity, personnel identification, food safety, agri-diagnostics, and veterinary. Medical application and forensics applications are the two largest segments in terms of application.
North America, Asia Pacific, Europe, MEA and Latin America are the key regions included in the study. North America emerged as the largest revenue-generating and fastest-growing region in the gene amplification technology market which is attributed to high investments in healthcare infrastructures, technological advancements, availability of government funds, and excessive research in the fields of genetic testing, diagnostics, and detection of critical diseases. This region is expected to maintain its dominance over the forecast period with a lucrative growth rate. Asia Pacific is expected to grow substantially attributing to favorable government initiatives towards the development of healthcare infrastructure. Growing economies such as China and India are expected to witness higher growth rates owing to increased research activity, lower cost, abundant manpower of skilled workers, and supportive government policies for research set up.
Major players in the gene amplification technologies market include Abbott Laboratories, QIAGEN N.V., Agilent Technologies Inc., Bayer Corporation, Rubicon Genomics, Becton, Roche Diagnostics, bioMérieux, Bio-Rad Laboratories, Cepheid, Life Technologies Corporation, Dickinson and Company, and Takara Bio, Inc. These players engage in various strategic initiatives including mergers, acquisitions in order to gain market share and excel in the long run.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.